Azatadine maleate in perennial allergic rhinitis: effects on clinical symptoms and choice reaction time.
1 The efficacy of the antihistamine azatadine maleate at maximum recommended dosage (4 mg/day) for 1 week was assessed relative to placebo in a double-blind crossover study of twenty patients with perennial allergic rhinitis. 2 Sixteen patients reported significant improvement in their clinical symptoms while taking the active drug. 3 The size of skin test weals for both histamine provocation and common inhalant allergens (prick test) diminished significantly after the azatadine treatment. There was no correlation between inhibition of skin reactions and symptom improvement. 4 Eight subjects reported sedative effects attributable to azatadine maleate. Their performance on a choice reaction to placebo occurred in the non-sedated group.
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D003533:Cyproheptadine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006633:Histamine Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D011930:Reaction Time / Q000187:drug effects; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D012882:Skin Tests
D006633:Histamine Antagonists; D006993:Hypnotics and Sedatives; D003533:Cyproheptadine; C006656:azatadine